Cti Biopharma Corp Drug Patent Portfolio
Cti Biopharma Corp owns 1 orange book drug protected by 3 US patents Given below is the list of Cti Biopharma Corp's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt | 25 Mar, 2030 | Active |
| US8153632 | Oxygen linked pyrimidine derivatives | 17 Jan, 2029 | Active |
| US9573964 | Oxygen linked pyrimidine derivatives | 05 May, 2028 | Active |
Latest Legal Activities on Cti Biopharma Corp's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Cti Biopharma Corp.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| transaction for FDA Determination of Regulatory Review Period | 14 Mar, 2024 | US9573964 |
| transaction for FDA Determination of Regulatory Review Period | 29 Feb, 2024 | US9573964 |
| Second letter to regulating agency to determine regulatory review period | 30 Sep, 2023 | US9573964 |
| Letter from FDA or Dept of Agriculture re PTE application | 28 Sep, 2023 | US9573964 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 31 Aug, 2022 | US8980873 |
| Initial letter Re: PTE Application to regulating agency | 01 Jul, 2022 | US9573964 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 19 Jan, 2022 | US9573964 |
|
Email Notification
Critical
| 19 Jan, 2022 | US9573964 |
|
Correspondence Address Change
Critical
| 18 Jan, 2022 | US9573964 |
|
Change in Power of Attorney (May Include Associate POA)
Critical
| 18 Jan, 2022 | US8980873 |
|
Email Notification
Critical
| 18 Jan, 2022 | US8980873 |
|
Correspondence Address Change
Critical
| 16 Jan, 2022 | US8980873 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 May, 2020 | US9573964 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 05 Sep, 2018 | US8980873 |
|
Recordation of Patent Grant Mailed
Critical
| 21 Feb, 2017 | US9573964 |
Cti Biopharma Corp's Family Patents
Cti Biopharma Corp drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 21.0% of its total global patent coverage. Click
below to unlock the full patent family tree.
Cti Biopharma Corp Drug List
Given below is the complete list of Cti Biopharma Corp's drugs and the patents protecting them.
1. Vonjo
Vonjo is protected by 3 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8980873 | 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt |
25 Mar, 2030
(5 years from now)
| Active |
| US8153632 | Oxygen linked pyrimidine derivatives |
17 Jan, 2029
(4 years from now)
| Active |
| US9573964 | Oxygen linked pyrimidine derivatives |
05 May, 2028
(3 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vonjo's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List